CeNeRx BioPharma, Inc.- Product Pipeline Review - Q4 2010

Global Markets Direct, November 2010, Pages: 51

CeNeRx BioPharma, Inc.– Product Pipeline Review – Q4 2010

Summary

Global Market Direct’s pharmaceuticals report, “CeNeRx BioPharma, Inc. - Product Pipeline Review - Q4 2010” provides data on the company’s research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.

This report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company’s corporate website, SEC filings, investor presentations and featured press releases, both from company and industry-specific third party sources, put together by Global Markets Direct’s team.

Scope

- CeNeRx BioPharma, Inc. - Brief company overview including business description, key information and facts, and its locations and subsidiaries.
- Review of current pipeline of CeNeRx BioPharma, Inc. human therapeutic division.
- Overview of pipeline therapeutics across various therapy areas.
- Coverage of current pipeline molecules in various stages of drug development, including the combination treatment modalities, across the globe.
- Product profiles for late stage and clinical stage products of CeNeRx BioPharma, Inc. with complete description of the product’s developmental history, mechanism of action, therapeutic class, target and major milestones.
- Recent updates of the CeNeRx BioPharma, Inc.’s pipeline in the last quarter.
- Key discontinued and dormant projects.
- Latest news and deals relating to the products.

Reasons to buy

- Evaluate CeNeRx BioPharma, Inc.’s strategic position with total access to detailed information on its product pipeline.
- Assess the growth potential of CeNeRx BioPharma, Inc. in its therapy areas of focus.
- Identify new drug targets and therapeutic classes in the CeNeRx BioPharma, Inc.’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas.
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps.
- Exploit collaboration and partnership opportunities with CeNeRx BioPharma, Inc..
- Avoid Intellectual Property Rights related issues.
- Explore the dormant and discontinued projects of CeNeRx BioPharma, Inc. and identify potential opportunities in those areas.

List of Tables
List of Figures
CeNeRx BioPharma, Inc. Snapshot
CeNeRx BioPharma, Inc. Overview
Key Information
Key Facts
CeNeRx BioPharma, Inc. – Research and Development Overview
Key Therapeutic Areas
CeNeRx BioPharma, Inc. – Pipeline Review
Pipeline Products by Stage of Development
Pipeline Products – Monotherapy
CeNeRx BioPharma, Inc. – Pipeline Products Glance
CeNeRx BioPharma, Inc. Clinical Stage Pipeline Products
Phase II Products/Combination Treatment Modalities
CeNeRx BioPharma, Inc.–Early Stage Pipeline Products
Pre-Clinical Products/Combination Treatment Modalities
CeNeRx BioPharma, Inc. – Drug Profiles
CXB722
Product Description
Mechanism of Action
R&D Progress
TriRima
Product Description
Mechanism of Action
R&D Progress
Ayrene
Product Description
Mechanism of Action
R&D Progress
Cannabinoid 040
Product Description
Mechanism of Action
R&D Progress
Cannabinoid-006
Product Description
Mechanism of Action
R&D Progress
Cannabinoid-007
Product Description
Mechanism of Action
R&D Progress
Cannabinoid-016
Product Description
Mechanism of Action
R&D Progress
Cannabinoid-070
Product Description
Mechanism of Action
R&D Progress
CX 009
Product Description
Mechanism of Action
R&D Progress
CX 2614
Product Description
Mechanism of Action
R&D Progress
CXB029
Product Description
Mechanism of Action
R&D Progress
CXB040
Product Description
Mechanism of Action
R&D Progress
CXB070
Product Description
Mechanism of Action
R&D Progress
CXB909
Product Description
Mechanism of Action
R&D Progress
CeNeRx BioPharma, Inc. – Pipeline Analysis
CeNeRx BioPharma, Inc. – Pipeline Products by Therapeutic Class
CeNeRx BioPharma, Inc. Pipeline Products By Target
CeNeRx BioPharma, Inc. – Pipeline Products by Route of Administration
CeNeRx BioPharma, Inc. – Recent Pipeline Updates
CeNeRx BioPharma, Inc. – Locations And Subsidiaries
Head Office
Recent Developments
Nov 02, 2010: CeNeRx's New Antidepressant TriRima Demonstrates Key Safety Benefit In Pivotal Safety Study
Jan 12, 2010: CeNeRx BioPharma Announces New Clinical Study Of CXB722 For The Treatment Of Anxiety
Feb 12, 2009: Cenerx Reports Enrollment Of Patient In Phase II Trial For Tririma
Oct 17, 2008: CeNeRx Initiates Phase II Clinical Trial For Tyrima
Jul 22, 2008: CeNeRx Plans To Initiate Phase II Clinical Trials For Tyrima
Jan 16, 2008: CeNeRx BioPharma Completes Phase l Clinical Trial For Tyrima
May 30, 2007: Strategic Partnership Gives CeNeRx Rights to Develop and Commercialize Extensive Cannabinoid Pipeline for Pain and Other Disorders
May 30, 2007: Strategic Partnership Gives CeNeRx Rights to Develop and Commercialize Extensive Cannabinoid Pipeline for Pain and Other Disorders
Mar 13, 2007: CeNeRx Announces Positive Phase I Results in First Human Trial Of TriRima
Jan 30, 2007: CeNeRx BioPharma Initiates Human Trials of Tyrima
Financial Deals Landscape
CeNeRx BioPharma, Inc., Deals Volume Summary, 2004 to YTD 2010
CeNeRx BioPharma, Inc., Deals Summary By Region, 2004 to YTD 2010
CeNeRx BioPharma, Inc., Deals Summary, 2004 to YTD 2010
CeNeRx BioPharma, Inc. Detailed Deal Summary
Venture Financing
CeNeRx BioPharma Raises $9 Million In Series C Financing
CeNeRx BioPharma Secures $4 Million Financing
CeNeRx BioPharma Secures $15 Million In Series B Financing
CeNeRx BioPharma Secures $18.5 Million In Series A Financing
Licensing Agreements
CeNeRx BioPharma Enters Into License Agreement With Krenitsky Pharmaceuticals
CeNeRx BioPharma Enters Into Licensing Agreement With PharmaNess Neuroscience
CeNeRx Enters Into Licensing Agreement With Krenitsky Pharmaceuticals
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

Customers who bought this item also bought

• Generic Defense Strategies: Lifecycle Management Strategies to Maximize Revenue in the Face of Growing Generic Competition
• Biodefense Industry - Market to Benefit from Federal Funding such as the BIO EDEP Fund to Support Security Plans
• Israel Life Sciences Market Analysis
• The Future of the Biodefense Industry: Regulation, Funding Opportunities & Company Profiles
• Sports and Fitness Nutrition - Global Strategic Business Report
• Private Tutoring - Global Strategic Business Report
• Education Services - Global Strategic Business Report
• United States Economic Report - Annual Subscription
• eLEARNING - Global Strategic Business Report
• The Global Missiles and Missile Defense Systems Market - Country Analysis: Market Profile